Both Retavase and TNKase are indicated only for managing acute myocardial infarction, and are not FDA-approved for acute ischemic stroke or pulmonary embolism. "tPA" is the abbreviation commonly used for the drug class that encompasses all tissue plasminogen activators. However, healthcare ...